All NewsFDA BriefsOncology IconsSpecial ReportsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision MedicineSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Triple Negative Breast Cancer with Andrew Seidman, MD and Joyce O'Shaughnessy, MD: Case 1

home / case-based-peer-perspectives / triple-negative-breast-cancer-case-1

Triple Negative Breast Cancer with Andrew Seidman, MD and Joyce O'Shaughnessy, MD

Joyce O'Shaughnessy, MD: Principle Third-Line Options for Patients With Metastatic TNBC

EP. 1: Joyce O'Shaughnessy, MD: Principle Third-Line Options for Patients With Metastatic TNBC

February 23rd 2016

Watch

Joyce O'Shaughnessy, MD: Efficacy Data Supporting the Use of Eribulin Mesylate

EP. 2: Joyce O'Shaughnessy, MD: Efficacy Data Supporting the Use of Eribulin Mesylate

February 23rd 2016

Watch

Joyce O'Shaughnessy, MD: Different Mechanisms of Action in Eribulin

EP. 3: Joyce O'Shaughnessy, MD: Different Mechanisms of Action in Eribulin

February 23rd 2016

Watch

Joyce O'Shaughnessy, MD: Main Indications for Dose Reduction With Eribulin

EP. 4: Joyce O'Shaughnessy, MD: Main Indications for Dose Reduction With Eribulin

February 23rd 2016

Watch

Andrew Seidman, MD: Principle Third-Line Options for Patients With Metastatic TNBC

EP. 5: Andrew Seidman, MD: Principle Third-Line Options for Patients With Metastatic TNBC

February 23rd 2016

Watch

Andrew Seidman, MD: Efficacy Data Supporting the Use of Eribulin Mesylate

EP. 6: Andrew Seidman, MD: Efficacy Data Supporting the Use of Eribulin Mesylate

February 23rd 2016

Watch

Andrew Seidman, MD: Different Mechanisms of Action in Eribulin

EP. 7: Andrew Seidman, MD: Different Mechanisms of Action in Eribulin

February 23rd 2016

Watch

Andrew Seidman, MD: Main Indications for Dose Reduction With Eribulin

EP. 8: Andrew Seidman, MD: Main Indications for Dose Reduction With Eribulin

February 23rd 2016

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2024 MJH Life Sciences

All rights reserved.